In Depth 26 Jun 2024 Biotech megadeals: Exploring the surge in $100M+ deals …molecule therapies driving megadeals in the biotech industry. “The Inflation Reduction Act granted large molecule therapies (gene and protein-based therapies, immunotherapies, hormonal regulators, and antibody-drug conjugates), a much longer patent… June 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 Novartis Takes Genmab’s Leukemia Drug Off the Market …a monoclonal antibody that targets CD20 proteins on the surface of leukemia cells. The antibody binds to the proteins, alerting the immune system, which can then hunt down and kill… January 22, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 Find Out what’s Hot in the Latin American Biotech scene …and antibody specificity testing. In these areas, it has developed its MTB Array for Tuberculosis Proteome Microarray and FastMAb for custom antibody development. CDI is also pursuing a Protein Capture… November 17, 2016 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 12 Apr 2017 Video Interview: How Morphosys Grew Into a Billion-Euro Biotech …biotech in Germany, Morphosys. Their topics ranged from Morphosys’ current pipeline and previous failures to the immuno-oncology hype and company culture. Morphosys started out with its proprietary antibody technology platform… April 12, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 Abcam Will Start Selling Over 700 Antibodies from Roche …to over 500 other antibodies. And, as Spring continues developing new antibodies, the antibody seller will have the rights to all products that Roche decides to commercialize. For its part,… January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Sponsored 27 Nov 2019 How to Address the Challenges of Biologics Discovery and Development …key market players enter the field, competition is increasing. In recent years, the biologics industry has become more versatile and has moved from being primarily antibody-focused to including other modalities,… November 27, 2019 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data …to its dual mode of action comprising both antibody-dependent cellular phagocytosis induction and IL-7R-pathway blockade, OSE-127 may represent a promising novel immunotherapy option for ALL patients, including cases with dysregulated… December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 6 Mar 2017 How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains …use bicyclic peptides to guide toxins in an approach similar to antibody-drug conjugates (ADCs); and they stand to outperform their antibody-guided counterparts. Kevin Lee, CEO of Bicycle Therapeutics, sat down… March 6, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2020 Argenx Follows up Phase III Success with Giant €785M Global Offering …III trial results earlier this week, where its lead candidate antibody drug, efgartigimod, improved motor symptoms of patients with the chronic autoimmune disease myasthenia gravis. Argenx is listed on the… May 29, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Dec 2017 Interviews, Reviews and Tops: Our Best Biotech Articles from 2017 …of approaches… https://www.labiotech.eu/tag/mrna-technology/ RNA saw its first major win in perhaps decades this year, with the positive Phase III results for Alnylam and Sanofi‘s candidate, patisiran. So how far has… December 26, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 19 Jul 2022 The biggest Asia-Pacific biotech investments in June 2022 …using artificial intelligence (AI) and robotics to automate many research techniques including antibody selection, cell line development and molecular screening. “The global life sciences automation industry has significant growth potential,”… July 19, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Jan 2019 15 European Biotech Companies to Watch in 2019 …by its IPO, Orchard is planning to complete clinical development for its three lead gene therapy candidates and hopefully get them to the market. The company will also be pushing… January 7, 2019 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email